Evaxion Biotech A/S(EVAX)

POST4.040.000.00%19:46 EST

4.04-0.15-3.58%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
  MT Newswires Live · 01-21
  European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
- Lake Street Sticks to Its Buy Rating for Evaxion Biotech (EVAX)
  TIPRANKS · 01-13
  Lake Street Sticks to Its Buy Rating for Evaxion Biotech (EVAX)
- Evaxion A/S Announces Expansion of AI-Immunology™ Platform Into Autoimmune Diseases and Outlines 2026 Milestones Including Biomarker Data, Clinical Efficacy Results, and Pipeline Advancements
  Reuters · 01-13
  Evaxion A/S Announces Expansion of AI-Immunology™ Platform Into Autoimmune Diseases and Outlines 2026 Milestones Including Biomarker Data, Clinical Efficacy Results, and Pipeline Advancements
- Evaxion A/S to Present 2026 Milestones at Biotech Showcase Conference
  Reuters · 01-07
  Evaxion A/S to Present 2026 Milestones at Biotech Showcase Conference
- European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week
  MT Newswires Live · 2025-12-27
  European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week
- BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire
  Reuters · 2025-12-19
  BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire
- Evaxion a/S - Co Retains Global Rights to Evx-B2 and Will Look for Another Potential Licensing Partner
  THOMSON REUTERS · 2025-12-19
  Evaxion a/S - Co Retains Global Rights to Evx-B2 and Will Look for Another Potential Licensing Partner
- Evaxion a/S - Msd Declines to Exercise Option for Evaxion's Gonorrhea Vaccine Candidate Evx-B2
  THOMSON REUTERS · 2025-12-19
  Evaxion a/S - Msd Declines to Exercise Option for Evaxion's Gonorrhea Vaccine Candidate Evx-B2
- Evaxion a/S - No Impact on Evaxion's Cash Runway Extending to Second Half of 2027
  THOMSON REUTERS · 2025-12-19
  Evaxion a/S - No Impact on Evaxion's Cash Runway Extending to Second Half of 2027
- Evaxion a/S - Eligible for up to $592 Mln in Milestone Payments Associated With the Development of Evx-B3
  THOMSON REUTERS · 2025-12-19
  Evaxion a/S - Eligible for up to $592 Mln in Milestone Payments Associated With the Development of Evx-B3
- Evaxion Provides Update on Msd Collaboration - Retains Global Rights to Gonorrhea Vaccine Candidate Evx-B2
  THOMSON REUTERS · 2025-12-19
  Evaxion Provides Update on Msd Collaboration - Retains Global Rights to Gonorrhea Vaccine Candidate Evx-B2
- Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
  GlobeNewswire · 2025-12-19
  Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
- European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
  MT Newswires Live · 2025-12-16
  European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
- European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
  MT Newswires Live · 2025-12-12
  European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
- European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
  MT Newswires Live · 2025-12-11
  European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
- European Equities Traded in the US as ADRs Little Changed in Monday Trading
  MT Newswires Live · 2025-12-09
  European Equities Traded in the US as ADRs Little Changed in Monday Trading
- Evaxion Unveils Promising Preclinical Data for Off-the-Shelf AML Vaccine EVX-04
  Reuters · 2025-12-08
  Evaxion Unveils Promising Preclinical Data for Off-the-Shelf AML Vaccine EVX-04
- Evaxion Unveils Promising Preclinical Data for AML Vaccine EVX-04 at ASH Meeting
  Reuters · 2025-12-07
  Evaxion Unveils Promising Preclinical Data for AML Vaccine EVX-04 at ASH Meeting
- European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
  MT Newswires Live · 2025-11-27
  European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
- European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading
  MT Newswires Live · 2025-11-25
  European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading
Company Profile
Company Name
Evaxion Biotech A/S
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.evaxionbiotech.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
- 2025-11-21
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2025-04-01
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-03-21
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-01-29
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-01-28
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-12-18
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-12-05
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-11-18
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-11-14
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-11-07
  Beneficial Ownership Change
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 2024-08-20
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-08-20
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-07-22
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-07-22
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-05-06
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers

1D
5D
Day
Week
Month

Loading ...

High

4.24

Open

4.24

Volume%

1.32

Low

3.90

4.19

T/O Rate

1.89%

To The Moon

Evaxion Biotech A/S(EVAX)

Company Profile

Most Discussed